Tumor reduction after SARS ‑CoV‑2 infection in a patient with lung cancer: A case report

Oncol Lett. 2024 Feb 22;27(4):169. doi: 10.3892/ol.2024.14302. eCollection 2024 Apr.ABSTRACTLung cancer is one of the most common malignancies worldwide. Since the global outbreak of the coronavirus disease 2019 (COVID-19) pandemic in 2020, the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on lung cancer has been extensively studied. Despite reports about SARS-CoV-2 infection inducing a significant increase in the number of medical visits for patients with cancer, the virus has also been reported to produce some unknown benefits. The present study reports the case of a patient with lung cancer whose tumor lesion was reduced in size after SARS-CoV-2 infection even though the therapeutic regimen remained unchanged. Although the mechanism involved is not yet understood, this case supports the novel idea of applying SARS-CoV-2 in oncolytic virotherapy.PMID:38455664 | PMC:PMC10918517 | DOI:10.3892/ol.2024.14302
Source: Oncology Letters - Category: Cancer & Oncology Authors: Source Type: research